Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A study published in The Lancet Diabetes & Endocrinology found that tirzepatide, a first-in-class dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, diminishes the risk of major kidney events when compared with dulaglutide, a long-acting GLP-1 receptor agonist, in patients with type 2 diabetes (T2DM)
General Strength
however, the clinical relevance of this finding in humans is uncertain, and this is not listed as a contraindication in UK or EU Summaries of Product Characteristics for licensed medicines in this class
Many patients are able to lose 10% of their body weight
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
